Repeat-File Evidence Desk

ILLUSTRATIVE PRODUCT DECISION GUIDE | PUBLIC-SOURCE AND SERVICE METHODOLOGY

No completed client matter is represented. This document demonstrates questions, evidence requirements, limitations and possible deliverables. It contains no verified findings about a named buyer or company. A matter, source access, fixed fee and timing require separate written acceptance.

---

1. Cover copy: question and promise

Repeat-File Evidence Desk

Repeat-file quality and exceptions: What is the authoritative product, trial and regulatory-record status?

Use this review when: FDA communication, study update, device recall or partner review.

Target reader: Life-science investors, device manufacturers, counsel and procurement.

Illustrative subtitle: A clearly bounded external-evidence review identifying what original records substantiate, which claims are contested and what the client must request before relying on an assertion.

2. The buyer decision and research boundary

The decision owner must resolve: **What is the authoritative product, trial and regulatory-record status?** The matter is activated by a documented event such as **fda communication, study update, device recall or partner review**. This specimen is intentionally subject-neutral. For the real commission, the research team must insert the actual named entity, decision date, jurisdiction, exact wording of the challenged claim and period before claiming anything factual.

Agreed scope model: Written pilot of up to ten defined file types, with sampling rules, turnaround assumptions and exclusions.

What is not automatically included: unbounded jurisdictions, confidential database access, professional regulated opinions, private surveillance, hardware or onsite testing, urgent escalation and any undisclosed third-party subscription costs.

3. What the buyer provides before instruction

- Exact name and identifiers of the relevant company, asset, product, person or project and its jurisdiction.
- The decision they must make, their deadline and the particular assertion or document that prompted it.
- Lawfully sharable materials, with any personal and confidential information minimised.
- Details of known adverse records, disputes and contradictory accounts, rather than a one-sided brief.
- Approval of the written scope, access conditions, final fee, permitted reliance and independent reviewer.

4. Investigative questions prepared for the real commission

- What is the authoritative product, trial and regulatory-record status?

- Which FDA device database establishes the relevant subject, version and reporting period?
- Could trial not approval overturn the decision-relevant statement?
- What original ClinicalTrials.gov supports an independent cross-check rather than repeating the same source?
- Which dated records would distinguish device name mismatch from a genuine discrepancy?
- What source result would justify a specialist referral rather than a research conclusion?

5. Evidence acquisition order and verification method

- **Resolve the subject.** Start with `FDA device database` and capture issuer, entity match, record date, retrieval timestamp and original identifier.
- **Triangulate.** Compare `ClinicalTrials.gov` against the first source, testing whether both genuinely derive from independent originals.
- **Establish sequence.** Examine `product manufacturer registration` and order assertion, contemporaneous record, amendment and current status.
- **Seek negative evidence.** Test `trial not approval`, `device name mismatch` and `recall absent due to search limitation` with documented competing hypotheses.
- **Document the cutoff.** Name what is inaccessible, subscription-controlled, outdated or outside jurisdiction, and stop when the evidence cannot support more.
- **Human review.** Route legal, audit, security, engineering, medical, valuation or licensing questions to an authorised professional if applicable.

Why an evidence analyst is involved: Reconcile product identifiers, sponsor identity, clinical registry and regulator notices. The value exists only when the recorded work improves the buyer's decision beyond readily accessible search results, an internal analyst or a self-service AI summary.

6. Ready-to-typeset example evidence matrix

Question/claim; First applicable original record; Best competing evidence; Illustrative state before casework; Next evidence action

Identity, legal capacity and exact subject; `FDA device database`; Alias/period mismatch; Not yet examined; Obtain verified legal or asset identifier

Main decision assertion; `ClinicalTrials.gov`; `trial not approval`; Not yet examined; Request original dated statement and counter-record

Material event timing; `product manufacturer registration`; `device name mismatch`; Not yet examined; Reconcile dated event and publication chronology

Adverse exception; Independent contrary source; `recall absent due to search limitation`; Not yet examined; Ask precise targeted contradictory question

Meaning of statuses (for the eventual real report):

Evidence state; Meaning for the decision owner

Supported; Applicable original records support the narrowly worded claim for the stated time and entity.

Partially supported; Some elements are established, while material qualifiers, scope or periods remain open.

Contradicted; A more reliable applicable record conflicts with the proposed assertion.

Unresolved; Accessible evidence is absent, ambiguous, outdated or conflicting; further documents are required.

Outside mandate; The question requires a reserved professional function or additional agreed research.

7. Concrete specimen outputs (without fictional findings)

Output committed for this product: Consistent file-by-file evidence cards, exception register and consolidated management view.

Suggested report artifacts:

- **Regulated Product State Brief**: rows for evidence question, entity match, issuer, record identifier, effective date, retrieval date, contrary document, confidence explanation and reviewer disposition.
- **Trial-Source Crosswalk**: a table distinguishing event dates, record publication dates, claim dates, subsequent amendment and unresolved chronological gaps.
- **Manufacturer Evidence Map**: a controlled clarification list addressed to the relevant source owner or instructing professional.
- A concise executive decision note stating what may be relied upon for the specified purpose and which matters remain unresolved.

Editorial visual specification: Include one actual evidence matrix or original-record timeline only when underlying evidence exists. Never insert decorative charts, fabricated relationships, arbitrary ratings or imaginary completed cases.

8. Source acquisition catalogue for this offer

These are real portals and competitor-method references to evaluate, not proof of any specific subject. Access, freshness, jurisdiction and licensing must be rechecked during production.

Ref; Primary source / comparator; Link; Evidence limitation and status

FDA-DEVICE; U.S. FDA: openFDA device recall API; https://open.fda.gov/apis/device/recall/how-to-use-the-endpoint/; WEB CHECKED 2026-10-12. Database refresh and product name ambiguity require original FDA reconciliation

FTC-ADS; U.S. FTC: Advertising substantiation standards FAQ; https://www.ftc.gov/business-guidance/resources/advertising-faqs-guide-small-business; WEB CHECKED 2026-10-12. US advertising context; scientific/health claims may require specialised testing not performed by Aperture

S16; U.S. FDA open data for devices; https://open.fda.gov/apis/device/; REGISTER STARTING POINT; NOT NEWLY RECHECKED. Source candidate; subject relevance, date and access must be verified case-by-case.

9. Deliberately adverse questions and professional boundary

- If `trial not approval`, does the strongest original record still justify the same assertion?
- Could `device name mismatch` result from a date mismatch, name collision, incomplete publication or source-update lag?
- What would demonstrate `recall absent due to search limitation` and require a 'cannot determine' outcome?
- **Professional boundary:** No medical advice, efficacy certification or approval determination.

10. How a reader commissions the real product

The reader identifies the subject, decision date and three most material questions and requests a **written scope and fixed fee** through the existing website pathway: `/specialist-divisions/pharmaceuticals-biotechnology-medical-device-intelligence/offers/repeat-file-desk/`. An initial enquiry must not contain confidential attachments. No work begins, payment occurs or information is treated as professionally verified until human acceptance, conflicts, lawful sourcing, pricing and the secure handoff process are complete. This illustrated manuscript does not constitute an offer to undertake regulated activity.

11. Production / reliance quality checklist

- Confirm the appointing client, exact research question, relevant location, decision date, conflicts, privacy, sanctions and licensing.
- Check original source identity, authority, issue date, effective date, retrieval timestamp, version and lawful access.
- Reproduce important calculations and compare at least one plausible contrary explanation.
- Keep allegations, regulatory findings, historical claims and unresolved matches distinct.
- Mark each proposed finding supported, partially supported, contradicted, unresolved or outside mandate; include missing-source requests.
- Confirm that illustrations do not imply a real engagement, completed investigation, certified outcome or affiliation with named comparators.
- Obtain final human sign-off on accuracy, legal boundaries, confidentiality, claims and publication version before release.

Visual publication policy: When instructed to generate a PDF later, follow the approved Aperture PDF visual master, original approved brand art, document control page and separate final human sign-off. There is no PDF yet.

Professional boundaries: Independent research support only. No legal, tax, investment, audit, valuation, brokerage, investigation requiring a specific professional licence or regulated opinion is implied. No confidential material should be sent before instructions.